Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Intradermal H5N1 Vaccine With or Without Topical Aldara
NCT03472976Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2018
- Primary completion
- Mar 2019
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of imiquimod in Avian Influenza (AI) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Geometric Mean Titers of Serum Hemagglutination Inhibition Antibodies at Day 43, Occurrence of All Serious Adverse Events and 3 more. Started Jun 2018; status: completed.
02
Drugs
imiquimod
03
Conditions
Avian Influenza (AI)
Beyond the preview
Go deeper on NCT03472976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03472976.